Navigation Links
Rigel Announces Proposed Public Offering of Common Stock
Date:5/25/2011

, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as for muscle disorders.

Forward-Looking Information is Subject to Risk and Uncertainty

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Rigel's expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Rigel will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Rigel will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.  Additional risks and uncertainties relating to the proposed offering, Rigel and its business can be found under the heading "Risk Factors" in Rigel's Quarterly Report on Form 10-Q filed with the SEC on May 3, 2011 and other filings with the SEC, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof. Rigel expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
2. Rigel Announces First Quarter Financial Results
3. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
4. Rigel to Present at Three Upcoming Investor Conferences
5. Rigel Announces Participation at Two Investor Conferences
6. Rigel to Present at JP Morgan Healthcare Conference
7. Rigel Announces Third Quarter 2009 Financial Results
8. Rigel Announces Presentations at Two Investor Conferences
9. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
10. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
11. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 1, 2015 Nevro Corp. (NYSE: NVRO ... innovative evidence-based solutions for the treatment of chronic pain, ... offering of its common stock consisting of 1,475,506 shares ... be sold by certain of its stockholders. In addition, ... to purchase up to an additional 590,202 shares of ...
(Date:6/1/2015)... , June 1, 2015 NEOVIA ONCOLOGY ... engaged in the development and commercialization of novel, ... it has met with the U.S. Food and ... filing of an Investigational New Drug (IND) application ... a result of the meeting, Neovia has clarified ...
(Date:6/1/2015)... June 1, 2015 Novel t ... drive growth , says   GBI Research ... (NSCLC) treatment market will be driven primarily by the introduction ... treatment settings, which either replace or combine with generic chemotherapies. ... Non-Small Cell Lung Cancer Market to 2020 - ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... Genomic Health , Inc. (Nasdaq: GHDX ... Financial Officer, will present at the 31st Annual Canaccord ... 2011 at 11:30 a.m. Eastern Time (ET).   ... of the presentation, visit the Investor Relations section of ...
... 2011 It,s back-to-school season and for many families, ... To view the multimedia assets associated with ... (Photo: http://photos.prnewswire.com/prnh/20110804/MM45457 ) Each ... U.S. are infested with this common, six-legged critter that ...
Cached Medicine Technology:Genomic Health to Present at the Canaccord Genuity Growth Conference 2Head Lice Returns to School: Five Tips to Avoid Panic and Worry 2
(Date:6/1/2015)... (PRWEB) June 01, 2015 More than 22 ... summer months when school is out and they lose access ... Month and America’s dairy farmers and milk companies are on ... need with The Great American Milk Drive. , In ... provided in the school cafeteria for the bulk of their ...
(Date:6/1/2015)... June 01, 2015 Northridge dentist ... now offering patients a promotion on Invisalign for a ... Invisalign treatment is reduced to $3,700. Patients can find ... complimentary consultation and discuss the extent of correction they ... cannot be combined with any other offer. , ...
(Date:6/1/2015)... Listen to Volvo’s Director of Connectivity Strategy, ... more granular data to create better customer oriented services. ... in Josep Celaya Gonzalez, CIO at MAPFRE, and Silvan ... automotive insurer, MAPFRE are well versed in capturing complex ... the driver. Award winning start-up ParkTAG offer an exciting ...
(Date:6/1/2015)... June 01, 2015 Hexagon Geospatial is ... is a new cloud-based subscription service that provides on-demand ... software. , Both ERDAS IMAGINE and ... Producer Online, which offers a subscription model for delivering ... need to be able to quickly and easily access ...
(Date:6/1/2015)... 2015 The session, entitled “Building the ... vice president of Elektrobit Automotive Americas, senior representatives ... it will be moderated by Andy Gryc of CX3 ... and complexity of in-vehicle software in connected vehicles and ... and how the wider ecosystem can fit into new ...
Breaking Medicine News(10 mins):Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 2Health News:Hexagon Geospatial Launches Cloud-Based Producer Online Suite 3Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 2Health News:Elektrobit Automotive, Ford and Delphi to Tackle In-Vehicle Software at TU-Automotive Detroit 2015 3
... Sept. 3 Endo Pharmaceuticals (Nasdaq: ENDP ) ... the treatment of a distinct form of bladder cancer. VALSTAR ... Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the ... be associated with unacceptable medical risks. VALSTAR represents a ...
... owners to warning signs of PTSD, experts say , THURSDAY, ... was unaware that she was racing dangerously down the freeway ... nose nudge her elbow. , She immediately slowed down. , ... warning her that her anxiety levels were rising, a dangerous ...
... , Briefing is the first ... , WASHINGTON, Sept. 3 The following is ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ) , ... Innovation will host a breakfast briefing on Capitol Hill titled "Education ...
... , EMERYVILLE, Calif., Sept. 3 Bionovo, Inc. (Nasdaq: ... from the phase 2 clinical trial of their lead drug candidate for ... Society for Gynecology (EGS) in Rome, Italy. , ... the safety and efficacy of two doses of Menerba versus placebo. The ...
... WASHINGTON, Sept. 3 The International Medical Interpreters ... building the organization,s international structure. The IMIA is proud ... Representative for Brazil. A medical interpreter trained in the ... now undergoing a Masters Program at Santa Catarina Federal ...
... , , ... and Drug Administration,s quest to dramatically reduce Salmonella-related food poisoning, ... country,s largest shell egg pasteurizer, opened a new state-of-the-art plant ... to eggs free from dangerous egg-related Salmonella-enteritidis. , , ...
Cached Medicine News:Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 2Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 3Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 4Health News:Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer 5Health News:Service Dogs Help Traumatized Veterans Heal 2Health News:Service Dogs Help Traumatized Veterans Heal 3Health News:Council for American Medical Innovation to Host Capitol Hill Breakfast Briefing on Education and Immigration: The Building Blocks of Innovation 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 3Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 4Health News:IMIA Interpreter Association Appoints Brazil Representative 2Health News:National Pasteurized Eggs Increases Access to Safe Pasteurized Shell Eggs With New Plant Opening During September's National Food Safety Education Month 2
Each handle is designed to fit a specific trephine size....
20 GA TITANIUM RETINAL FORCEPS...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
Medicine Products: